AtaiBeckley (ATAI) Share-based Compensation (2020 - 2026)
AtaiBeckley (ATAI) reported Share-based Compensation of $21.4 million for Q3 2025, up 4180.0% on a YoY basis from $500000.0 in Q3 2024, and up 921.97% sequentially from $2.1 million in Q2 2025.
AtaiBeckley (ATAI) Share-based Compensation (2020 - 2026) Analysis & Trends
AtaiBeckley's Share-based Compensation history runs 2 years deep, the most recent figure standing at $50.8 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 1414.16% year-over-year to $50.8 million in Q1 2026; TTM through Mar 2026 was $50.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $14.2 million, down 44.24% from the prior year.
- Share-based Compensation improved to $21.4 million in Q3 2025, from $2.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $50.8 million in Q1 2026 and bottomed at $3.4 million in Q1 2025.
- A 5-year average of $6.5 million and a median of $6.0 million in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation plunged 99.38% in 2022 and jumped 5750.47% in 2024, its largest moves.
- Tracing ATAI's Share-based Compensation over 5 years: stood at $13.4 million in 2021, then decreased by 9.39% to $12.1 million in 2022, then sank by 39.83% to $7.3 million in 2023, then climbed by 15.02% to $8.4 million in 2024, then soared by 154.7% to $21.4 million in 2025.
- Business Quant data shows ATAI's Share-based Compensation at $21.4 million in Q3 2025, $2.1 million in Q2 2025, and $8.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | 21.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.80 Mn |
| Mar 31, 2026 | 50.80 Mn |
| Sep 30, 2025 | 21.40 Mn |
| Sep 30, 2025 | 21.40 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 8.40 Mn |
| Dec 31, 2024 | 8.40 Mn |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 6.26 Mn |
| Jun 30, 2024 | 6.26 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Dec 31, 2023 | 7.31 Mn |
| Dec 31, 2023 | 7.31 Mn |
| Sep 30, 2023 | 4.86 Mn |
| Sep 30, 2023 | 4.86 Mn |